Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 07, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
November 04, 2019 07:00 ET
|
Trevena Inc.
Company expects to resubmit NDA for oliceridine in Q1 2020 Acute migraine proof-of-concept study for TRV250 initiated Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
October 28, 2019 07:05 ET
|
Axsome Therapeutics, Inc.
Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more likely to prescribe AXS-07 over current and...
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
October 28, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Enrollment in MOMENTUM Phase 3 migraine trial of AXS-07 in patients with history of inadequate response nearly complete; on track for topline results in 4Q 2019 First patient dosed in new INTERCEPT...
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
September 05, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response...
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
August 20, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Trevena Reports Second Quarter 2019 Results
August 07, 2019 07:00 ET
|
Trevena Inc.
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as...
AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
May 09, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced...
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
May 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator ...
Trevena Reports Fourth Quarter and Full Year 2018 Results
March 13, 2019 07:00 ET
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...